+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Migraine Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 135 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4617267
The Migraine Therapeutics Market is expected to register a healthy CAGR of nearly 9.5% during the forecast period.

COVID-19 is a global public health crisis that has impacted almost every industry, and its long-term effects are expected to affect industry growth over the forecast period. According to the titled "Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users" published in BMC neurology in September 2021, although the number of migraine attacks decreased, the proportion of stress-related migraine attacks peaked at 53%. during COVID-19. Additionally, according to the study titled "COVID‐19 and Headache Medicine: A Narrative Review of Non‐Steroidal Anti‐Inflammatory Drug (NSAID) and Corticosteroid Use" published in the Headache in July 2021, during the COVID19 pandemic, there may be an increase in the number of patients with headache as their primary complaint. Hence, COVID-19 has a significant impact on the migraine therapeutics market.

Growing awareness of migraine and treatment options, rising R&D spending leading to a massive pipeline of products, and an increase in the prevalence of migraines with high unmet needs are all contributing to the global growth of the migraine therapeutics market.

The various strategic activity by the key market players such as product launch and product approval as well as merger and acquisition boost the market over the forecast period. For instance, In March 2021, AbbVie received the Phase 3 PROGRESS trial evaluating atogepant (QULIPTA in the United States), an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the preventive treatment of chronic migraine in adults, met its primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo, for both the 60 mg once daily (QD) and 30 mg twice daily (BID) doses, across the 12-week treatment period.

Additionally, in September 2021, The United States Food and Drug Administration (FDA) has approved QULIPTA (atogepant) to AbbVie for the prevention of episodic migraine in adults, QULIPTA is the world's first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) developed specifically for migraine prevention.

However, the migraine therapeutics market is hampered by a lack of proper diagnosis and undiagnosed cases, drug side effects, increased preference for alternative therapies, and generic penetration.

Key Market Trends

Triptans Are Expected to Grow at a Healthy CAGR During the Forecast Period

Triptans are a newer class of drug that increases serotonin levels in the brain, reducing inflammation and constricting blood vessels, effectively ending a migraine. Triptans constrict blood vessels in the brain and block pain pathways. These ergotamines have been found to be more migraine-specific than previous ergotamines. Almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan (Imitrex), sumatriptan and naproxen (Treximet), and zolmitriptan are some of the triptans available (Zomig). Sumatriptan and naproxen sodium (Treximet), a single-tablet combination, have been shown to be more effective than either medication alone in alleviating migraine symptoms.

Furthermore, as per the study titled "Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine" published in JAMA Network in October 2020, Ditans and Gepants were associated with less efficacy compared with triptans, whereas Gepants were associated with fewer adverse events compared with triptans. Thus, due to the higher efficacy of the triptans, it is expected to rise in demand for it thereby boosting the segment over the forecast period.

However, over the forecast period, product launches and market approvals for drugs in the triptan class will increase. For instance, in January 2020, Eli Lilly and Company has launched the REYVOW (lasmiditan) C-V 50 mg and 100 mg tablets, an oral medication for the acute treatment of migraine with or without aura in adults.

Thus, all aforementioned factor such higher efficacy of triptan and new product launches expected to boost the market.

North America Lead the Market during the forecast period

North America is expected to dominate the overall market and is projected to maintain its position until 2027. High prevalence, increasing adoption of novel therapeutics, and a large target population in the United States are the factors that contribute to the country's dominance.

According to the article published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, higher prevalence is expected to boost the migraine therapeutics market in the United States. There have also been many new therapeutics that are launched recently. For Instance, in December 2019, the United States Food and Drug Administration approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults.

Additionally, over the forecast period, various strategic activities by key market players such as product launch and approval, as well as mergers and acquisitions, will boost the market. In November 2021, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc., formed a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT in the United States, and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults.

All these factors are supporting North America to dominate the market.

Competitive Landscape

The Migraine Therapeutics market is highly fragmented with the presence of large number of local and international players. Key players are adopting different growth strategies to enhance their market presence such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. somne of the key market players includes Amgen, Teva Pharmaceutical, Eli Lilly and Company, GlaxoSmithKline etc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness about Migraine and its Treatment Options
4.2.2 Increasing R&D Expenditures Leading to High Pipeline Products
4.2.3 Increasing Prevalence of Migraines along with High Unmet Needs
4.3 Market Restraints
4.3.1 Adverse Effects of Drugs
4.3.2 Lack of Proper Diagnosis and Increasing Undiagnosed Cases
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapeutics
5.1.1 Pain-relieving Medications Analgesics Triptans Ergot Alkaloids Others
5.1.2 Preventive Medications Blood pressure-lowering Medications Anticonvulsant Drugs Calcitonin Gene-related Peptide (CGRP) Antagonists Other Preventative Therapies
5.2 Route of Administration
5.2.1 Oral & Nasal
5.2.2 Injectables
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Abbvie Inc.
6.1.3 AstraZeneca
6.1.4 Eli Lilly and Co.
6.1.5 GlaxoSmithKline
6.1.6 Merck & Co., Inc.
6.1.7 Pfizer
6.1.8 Bausch Health
6.1.9 Teva Pharmaceuticals
6.1.10 Novartis AG
6.1.11 Eisai Co., Ltd.,
6.1.12 Abbott Laboratories

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen
  • Abbvie Inc.
  • AstraZeneca
  • Eli Lilly and Co.
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Pfizer
  • Bausch Health
  • Teva Pharmaceuticals
  • Novartis AG
  • Eisai Co., Ltd.,
  • Abbott Laboratories